Drugs / SUVN-G3031
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04072380 | Sep 2019 → Jun 2023 | narcolepsy | Suven Life Sciences Limited | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02881294 Comparator | Aug 2016 → Sep 2017 | cognitive disorder | Suven Life Sciences Limited | Completed | No outcome recorded |
| Phase 1 | NCT02342041 Comparator | Sep 2014 → Jun 2015 | cognitive disorder | Suven Life Sciences Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SUVN-G3031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02342041 ↗ |
| Action | Inhibit | “histamine-3 receptor (H3R) inverse agonist” PMID 32399853 ↗ Jul 2020 |
| Route | Oral | “SUVN-G3031 administered orally once a day” NCT02342041 ↗ |